TOP STORIES
respiratory
Lung cancer

First targeted therapy approved to prevent recurrence of early stage NSCLC


Osimertinib (Tagrisso) has been TGA registered as adjuvant therapy after tumour resection in early stage, EGFR-mutated non-small cell lung cancer (NSCLC). It is the first targeted therapy available to prevent recurrence of disease in this patient group. The evidence comes from the...

Osimertinib (Tagrisso) has been TGA registered as adjuvant therapy after tumour resection in early stage, EGFR-mutated non-small cell lung cancer...

Read more